2 Millionaire-Maker Stocks to Hold for the Next 10 Years

The article argues Alphabet and Eli Lilly remain attractive long-term buys, citing Alphabet's AI-enhanced search, cloud growth, YouTube streaming, and Waymo autonomy as multi-year growth drivers. Eli Lilly is highlighted for its weight-loss franchise, AI drug discovery efforts, and pipeline that could extend exclusivity and add billions in revenue. The piece is opinionated and forward-looking rather than event-driven, so near-term price impact is likely limited.

Analysis

This is really a debate about duration, not valuation. Both names are being pitched as long-horizon compounders, but the near-term asymmetry is different: GOOGL has multiple monetization vectors that can offset capex overhang, while LLY is more binary because execution on pipeline breadth and patent-life extension directly determines how much of today’s premium persists. The market is likely underpricing how much optionality matters when core businesses are already scaled; incremental upside comes from adjacency conversion rather than category expansion.

For GOOGL, the second-order effect is that AI spend is not just a cost line — it is a distribution weapon that can strengthen search economics while also widening the moat in cloud and video. The underappreciated catalyst is YouTube: if streaming continues taking share from linear TV, ad inventory quality should improve faster than headline viewer growth, supporting pricing power. Waymo is the real call option, but it should be viewed as a years-long free optionality asset with partner leverage; Uber is a likely operational beneficiary before Alphabet fully monetizes the platform, so the ecosystem may get paid earlier than the core shareholder.

For LLY, the key issue is whether AI-driven discovery meaningfully compresses R&D timelines or merely improves hit rate at the margin. If it works, the economic lever is huge: a modest extension of effective exclusivity on one or two major drugs can matter more than years of portfolio growth. The risk is that investors are extrapolating a best-case obesity franchise into a permanent growth regime, when in reality the stock can de-rate quickly if trial cadence disappoints, pricing pressure intensifies, or the market decides the multiple already reflects most of the pipeline value.

Key Decisions for Investors

• Add to GOOGL on any 5-8% pullback over the next 1-3 months; use it as a lower-beta AI compounder with multiple shots on goal, targeting 15-20% upside over 12 months if cloud and YouTube reaccelerate.
• Buy LLY selectively, but only with a staggered entry over 2-4 weeks; the stock is a quality hold for 2-3 years, yet near-term multiple compression risk is high if obesity growth normalizes.
• Pair trade: long GOOGL / short a higher-multiple AI platform name with weaker cash flow conversion over the next 6-12 months; GOOGL has better downside support from existing monetization and less execution fragility.
• For investors already long LLY, hedge via out-of-the-money puts into major clinical readouts or pricing-policy headlines; the name can gap down 10-15% on sentiment shifts even if the long-term thesis remains intact.
• Add UBER only as a tactical spillover beneficiary on Waymo deployment news; treat it as an ecosystem trade, not a core thesis, with a 3-6 month horizon and event-driven upside.